Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 12 Oct - Intimation of allotment of Equity Shares upon exercise of stock options under the Entero Employee Stock Option Plan 2023
Source: Bse
Entero Healthcare Solutions Limited (ENTERO)
Micro CapPharma stocks · Micro cap · NSE
Entero Healthcare is a leading Indian healthcare supply chain specialist, among the top three distributors by revenue. It offers demand fulfillment and generation solutions for pharma and MedTech products, operating pan-India with 136 warehouses across 520+ districts. The company has a track record of 51 acquisitions.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result16 Aug, 12:33 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
68BullishSMA20 -4.4% / mo · RSI oversold · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 46
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
ENTEROD candles · FIT view+19.5%Latest close ₹1485.30 on 2026-10-21
Bar
-2.3%
RSI
28
MACD hist
-30.60
52W pos
55%
2026-10-21O ₹1519.50H ₹1537.20L ₹1459.00C ₹1485.30Vol 1.1L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ENTERONifty PharmaNifty 500
- ENTERO
- +22.0%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +28.5 pp
Chart stats
21 Oct 2026- From 52W high
- -22.6%
- 52W range position
- 55%
- ATR (14)
- 4.8%
- Volume vs 20D
- 0.84x
- Avg traded value
- ₹21 Cr
- 20D price channel
- ₹1,459 - ₹1,875
₹1,920
₹944 - ₹1,920
₹71
Latest completed session
20-session average
26.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST37
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +38.2% · PAT +73.3% YoY
Technical
Bullish68
Price trend and sector-relative-strength timing.
Valuation
Legacy model-14.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence69
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +38% YoY · PAT +73% YoY · margin expansion · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,940 Cr | +38.2% | +1.6% |
| EBITDA | ₹97 Cr | +94.0% | +12.8% |
| Operating margin | 5.0% | +140 bps | +50 bps |
| PAT | ₹52 Cr | +73.3% | +15.6% |
| PAT margin | 2.7% | +54 bps | +32 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 53.50
- P/B
- 4.09
- EV/EBITDA
- 21.06
- Market Cap
- 6906.00Cr
Profitability
- ROE
- 6.94%
- ROCE
- 10.50%
- ROA
- 4.67%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 30.00%
- EPS 5Y
- 57.00%
- Revenue 3Y
- 26.00%
- EPS 3Y
- 130.00%
Balance Sheet
- Debt/Equity
- 0.40
- Interest Coverage
- 4.89×
- Altman Z
- 5.24
- Book Value
- 388.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 96.00 Cr
- EPS TTM
- 28.82
Shareholding
- Promoter Hold
- 52.40%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 66%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 1,940+1.6% vs prev
Net Profit
₹ CrLatest: 52.0+15.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 28. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~4.6% over last month) — short-term momentum negative.
- RSI(14) at 28 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 23% off 52W high · 57% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
85
RS percentile
Stage 2 UptrendEstablished S2
1M return
-17.3%
3M return
+22.0%
6M return
+18.2%
1Y return
+34.6%
RS 1D
+1
RS 20D
-5
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 9.2% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +6.8%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
20 Jul 2026
S2 age
65 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 144.11-0.32%
RS vs Nifty 500144
Valuation & peers
U-Score 37 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 37 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth23/25
Quality0/20
Balance Sheet8/15
Cash Flow1/10
Piotroski
7/9 (+5)
Penalties
0
Raw sum
37
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
37/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 7/9.
- Growth contributes 23/25 to the score.
- Balance sheet contributes 8/15 to the score.
Main drags
- Fair-value margin of safety is negative at -14.5%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
53.5
PB
4.1
EV/EBITDA
21.1
ROE
6.9%
ROCE
10.5%
FCF Yield
—
Debt/Equity
0.4
MoS
-14.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
37
Previous: 37
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-14.5%
Previous: -16.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
37
37
37
37
37
37
37
37
37
37
37
37
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹501.6
-196.1% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,296.9
-14.5% MoS
PEG
0.62
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
AARTIPHARM
Micro
Aarti Pharmalabs Limited
Pharmaceuticals
match 139
32
35.4
8.6%
+20%
WATCHLIST
ADVENZYMES
Micro
Advanced Enzyme Technologies Limited
Pharmaceuticals
match 138
47
19.0
10.2%
-119%
FAIR VALUE
AARTIDRUGS
Micro
Aarti Drugs Limited
Pharmaceuticals
match 135
36
19.4
13.4%
-321%
WATCHLIST
BLISSGVS
Small
Bliss GVS Pharma Limited
Pharmaceuticals
match 134
39
51.4
11.8%
-8%
WATCHLIST
SANOFI
Small
Sanofi India Limited
Pharmaceuticals
match 133
53
15.8
47.1%
-305%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-02T20:32:57.513Z
Management commentary snapshot
Entero Healthcare reported strong Q4FY26 and FY26 results, with LFL revenue growth of 43.1% and 31.5% respectively. EBITDA margins expanded to 4.5% in Q4 and 4.0% for FY26, driven by improved working capital efficiency and operating cash flow generation of INR 96.2 Cr for the full year.
The company demonstrated strong execution, meeting its FY26 guidance across key financial metrics. Organic growth significantly outpaced the market, and strategic acquisitions, particularly in MedTech, are expanding the addressable market and margin profile. Operational efficiencies are improving, supporting cash flow generation.
Growth engines
Market Consolidation
PositiveManagement expects to benefit from market consolidation, with large/national distributors' share rising to 20-30% by FY28.
Strategic Acquisitions
PositiveThe company closed 7 acquisitions in FY26, including 3 in MedTech, contributing to a track record of 51 acquisitions since inception.
MedTech Expansion
PositiveExpanded beyond pharma into MedTech, broadening addressable opportunity. MedTech revenue is expected to cross INR 1,000 Cr in FY27.
Proprietary Technology Platform
PositiveLeveraging its proprietary technology platform with integrated business intelligence tools to drive efficiencies and growth.
Capacity and execution
Warehouses
PositiveIncreased to 136 in FY26 from 101 in FY25.
Retail Customers
PositiveIncreased to 105,300+ in FY26 from 95,300+ in FY25.
Districts Covered
PositiveIncreased to 523 in FY26 from 500 in FY25.
SKUs Handled
PositiveIncreased to 97,500+ in FY26 from 80,600+ in FY25.
Tailwinds
MedTech Market Growth
PositiveThe MedTech market is large (USD 33.2bn FY23) and growing (10-11% CAGR FY23-FY28), offering higher margin profiles.
Shift to Large Distributors
PositiveIndia is witnessing a shift from standalone/traditional distributors to large/national distributors with wider presence.
Technological Advances
PositiveTechnological advances are supporting operational efficiencies in distribution.
Risk radar
Economic Performance
NeutralThe company's performance is subject to the performance of the Indian economy and various international markets.
Competition
NeutralThe company operates in a highly fragmented and competitive market, both in India and worldwide.
Strategy Implementation
NeutralRisks include the company’s ability to successfully implement its strategy and achieve future levels of growth and expansion.
Technological Changes
NeutralThe company is exposed to risks related to technological implementation, changes, and advancements.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
The company provides both annual (FY26 vs FY25) and quarterly (Q4FY26 vs Q4FY25, and sequential Q4FY26 vs Q3FY26) comparisons. YoY is crucial for assessing overall annual performance and growth trends, while QoQ highlights sequential momentum, especially in operating cash flow and working capital efficiency improvements.
Sector KPIs management disclosed
Domestic Formulations Growth (Organic LFL)
PositiveOrganic revenue growth on LFL basis was 15.6% YoY for FY26, outperforming IPM growth by 1.6x. Q4FY26 organic LFL growth was 17.1% YoY, 1.4x IPM growth.
Gross Margin
PositiveGross margin improved by 78bps YoY to 10.3% for FY26. In Q4FY26, gross margin improved by 109bps YoY to 10.9%.
EBITDA Margin
PositiveEBITDA Margin improved by 67bps YoY to 4.0% for FY26. In Q4FY26, EBITDA Margin improved by 85bps YoY to 4.5%.
Net Operating Working Capital (Days)
PositiveNWC days improved to 59 days in Q4FY26 from 64 days in Q3FY26. For FY26, NWC days improved to 68 from 70 in FY25.
Management forward view
FY26 Performance
PositiveManagement states FY26 was a year of significant progress, delivering on all guidance parameters for revenue growth, EBITDA margin, and operating cash flow.
FY27 Outlook
PositiveManagement expresses renewed confidence for FY27 to build on momentum and capture the massive consolidation opportunity in the healthcare supply chain.
MedTech Contribution
PositiveManagement expects the MedTech segment, including FY26 acquisitions, to contribute over INR 1,000 Cr in FY27.
FY27 Guidance
PositiveManagement guides for 23.0% YoY revenue growth (excluding new acquisitions), 5.0% EBITDA Margin, and 50% Operating Cashflow to EBITDA Conversion Ratio for FY27.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Revenue Growth (YoY) | 29.3% (FY26 reported), 42.6% (Q4FY26 reported) | FY27 guidance of 23.0% YoY (excluding new acquisitions) |
| EBITDA Margin | 4.0% (FY26), 4.5% (Q4FY26) | FY27 guidance of 5.0% |
| Operating Cashflow to EBITDA Conversion | 36.2% (INR 96.2 Cr OCF vs INR 266 Cr EBITDA for FY26) | FY27 guidance of 50% |
| MedTech Revenue Contribution | Expected to cross INR 1,000 Cr in FY27 | Actual contribution and growth from the MedTech segment |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
69Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 59th percentile of the scored universe and 46th percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
54 docs text-extracted · 22 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
59th percentile
overall median 67 · Pharma: 46th pctile, median 70 · Micro: 38th pctile, median 73
Evidence depth
Financial-only
54 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸4/4 latest quarters had positive YoY PAT growth.
- ▸Latest 3 quarters had positive YoY PAT growth.
Trust risks
- ▸Only 1 years of positive FCF.
- ▸ROE is low at 6.9%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Entero Healthcare Solutions Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Sep - Entero Healthcare to attend Arihant Capital virtual group meeting on September 29, 2026.
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Management 24 Aug - Rajesh Shashikant Dalal’s independent director tenure ends on August 24, 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Management 13 Jul - Rajesh Dalal will not seek reappointment; ceases as Independent Director on August 24, 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Cessation 13 Jul - Rajesh Shashikant Dalal will cease as independent director and committee chair on August 24, 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Change in Management 26 Jun - Board approved 1,475 ESOP shares and revised independent director reappointments from August 25, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 26 Jun - Board has approved allotment of 1,475 (One Thousand Four Hundred and Seventy-Five) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, to the …
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 11 Jun - The Board has approved the allotment of 3,420 (Three Thousand Four Hundred and Twenty) Equity Shares of Rs. 10/- (Rupees Ten) each of the Company, …
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.